Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease

Open access

Abstract

Aggregated insoluble tau is one of two defining features of Alzheimer’s disease. Because clinical symptoms are strongly correlated with tau aggregates, drug development and clinical diagnosis need cost-effective and accessible specific fluid biomarkers of tau aggregates; however, recent studies suggest that the fluid biomarkers currently available cannot specifically track tau aggregates. We show that the microtubule-binding region (MTBR) of tau containing the residue 243 (MTBR-tau243) is a new cerebrospinal fluid (CSF) biomarker specific for insoluble tau aggregates and compared it to multiple other phosphorylated tau measures (p-tau181, p-tau205, p-tau217 and p-tau231) in two independent cohorts (BioFINDER-2, n = 448; and Knight Alzheimer Disease Research Center, n = 219). MTBR-tau243 was most strongly associated with tau-positron emission tomography (PET) and cognition, whereas showing the lowest association with amyloid-PET. In combination with p-tau205, MTBR-tau243 explained most of the total variance in tau-PET burden (0.58 ≤ R 2 ≤ 0.75) and the performance in predicting cognitive measures (0.34 ≤ R 2 ≤ 0.48) approached that of tau-PET (0.44 ≤ R 2 ≤ 0.52). MTBR-tau243 levels longitudinally increased with insoluble tau aggregates, unlike CSF p-tau species. CSF MTBR-tau243 is a specific biomarker of tau aggregate pathology, which may be utilized in interventional trials and in the diagnosis of patients. Based on these findings, we propose to revise the A/T/(N) criteria to include MTBR-tau243 as representing insoluble tau aggregates (‘T’).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02443-z

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Associations between CSF biomarkers and amyloid-PET and tau-PET. a,b, Associations between CSF biomarkers and amyloid-PET (a) and tau-PET (b). First two columns show scatter-plots of MTBR-tau243 (first column) and pT217/T217 (second column) and amyloid-PET (n = 268) or tau-PET (n = 443) in BioFINDER-2 participants, color-coded by diagnosis and amyloid status. Linear regression models, adjusting for age and sex, were used to obtain β, P values (asterisks) and R2 shown in the plots. Scatter-plots for all the biomarkers in both cohorts are shown in Extended Data Figs. 1 and 2. The third and fourth columns show standardized β (βstd) of the association between each CSF biomarker and amyloid- or tau-PET in BioFINDER-2 and Knight ADRC participants (n = 219; except for pT231/T231 in which n = 184 for all cases), respectively. Solid and dashed lines show standardized β (central dot) and 95% CI when all participants or only amyloid-positive participants (BioFINDER-2, amyloid-PET, n = 172, tau-PET, n = 287; Knight ADRC, n = 136; except for pT231/T231 in which n = 117) were included, respectively. Asterisks (crosses) show the highest or not significantly different standardized β in all (amyloid-positive only) participants, in each cohort and outcome based on bootstrapping. Thus, those biomarkers without asterisks or crosses have statistically weaker correlations. Aβ-positive participants were selected based on CSF Aβ42/40 previously validated cutoff values (CSF Aβ42/40 < 0.08 in BioFINDER-2 and CSF Aβ42/40 < 0.0673 in Knight ADRC). Association P values were derived from two-sided tests and bootstrapping P values were obtained from one-sided tests, all without adjustment for multiple comparisons. All P values from associations between CSF biomarkers and amyloid-PET and tau-PET were <0.001.
Fig. 1 Associations between CSF biomarkers and amyloid-PET and tau-PET. a,b, Associations between CSF biomarkers and amyloid-PET (a) and tau-PET (b). First two columns show scatter-plots of MTBR-tau243 (first column) and pT217/T217 (second column) and amyloid-PET (n = 268) or tau-PET (n = 443) in BioFINDER-2 participants, color-coded by diagnosis and amyloid status. Linear regression models, adjusting for age and sex, were used to obtain β, P values (asterisks) and R2 shown in the plots. Scatter-plots for all the biomarkers in both cohorts are shown in Extended Data Figs. 1 and 2. The third and fourth columns show standardized β (βstd) of the association between each CSF biomarker and amyloid- or tau-PET in BioFINDER-2 and Knight ADRC participants (n = 219; except for pT231/T231 in which n = 184 for all cases), respectively. Solid and dashed lines show standardized β (central dot) and 95% CI when all participants or only amyloid-positive participants (BioFINDER-2, amyloid-PET, n = 172, tau-PET, n = 287; Knight ADRC, n = 136; except for pT231/T231 in which n = 117) were included, respectively. Asterisks (crosses) show the highest or not significantly different standardized β in all (amyloid-positive only) participants, in each cohort and outcome based on bootstrapping. Thus, those biomarkers without asterisks or crosses have statistically weaker correlations. Aβ-positive participants were selected based on CSF Aβ42/40 previously validated cutoff values (CSF Aβ42/40 < 0.08 in BioFINDER-2 and CSF Aβ42/40 < 0.0673 in Knight ADRC). Association P values were derived from two-sided tests and bootstrapping P values were obtained from one-sided tests, all without adjustment for multiple comparisons. All P values from associations between CSF biomarkers and amyloid-PET and tau-PET were <0.001.CC BY · PubMed Central
Fig. 2 Proportion of variation of CSF biomarker levels explained by amyloid-PET and tau-PET. a,b, Partial R2 values are displayed within the columns and the percentages of partial R2 over the total R2 of the model are indicated above each column for BioFINDER-2 (a) and Knight ADRC participants (b). These values were computed using individual CSF biomarkers as outcomes and amyloid and tau measures as predictors in linear regression models adjusted for age and sex, within each CSF biomarker and cohort. The percentages may not sum up to 100% due to potential shared variance. The biomarkers are arranged from left to right based on the increasing contribution (%) of tau to their levels.
Fig. 2 Proportion of variation of CSF biomarker levels explained by amyloid-PET and tau-PET. a,b, Partial R2 values are displayed within the columns and the percentages of partial R2 over the total R2 of the model are indicated above each column for BioFINDER-2 (a) and Knight ADRC participants (b). These values were computed using individual CSF biomarkers as outcomes and amyloid and tau measures as predictors in linear regression models adjusted for age and sex, within each CSF biomarker and cohort. The percentages may not sum up to 100% due to potential shared variance. The biomarkers are arranged from left to right based on the increasing contribution (%) of tau to their levels.CC BY · PubMed Central
Fig. 3 Longitudinal CSF biomarkers change by baseline amyloid and tau status. Rates of change in CSF biomarkers per baseline amyloid (A) and tau (T) status are depicted (pT231/T231: n = 218, rest: n = 220). Individual rates of change are represented by dots. Trajectories for each group are displayed as boxplots, which were generated using linear mixed models (the central band represents the median, the lower and upper hinges correspond to the first and third quartiles and the whiskers depict the maximum/minimum value or 1.5 × interquartile range from the hinge, whichever is lower). Differences among all groups were assessed using Kruskal–Wallis tests and pairwise Wilcoxon tests were employed for post hoc comparisons. Asterisks indicate the P values from two-sided tests without correction for multiple comparisons. Longitudinal CSF data was available only in BioFINDER-2. Amyloid-positive participants were identified using a previously validated cutoff for CSF Aβ42/40 (CSF Aβ42/40 < 0.08). Tau positivity was determined based on tau-PET SUVR in the meta-ROI (Braak I-IV, SUVR > 1.32). ROI, region of interest. The actual P values for A−T− versus A+T− were P = 0.011 (pT205/T205); for A−T− versus A+T+ were P = 0.011 (pT181/T181), P = 0.014 (pT205/T205), P = 0.617 (pT217/T217) and P = 0.980 (pT231/T231); and for A+T− versus A+T+ were P = 0.788 (pT205/T205), P = 0.007 (pT231/T231). All other comparisons yielded P < 0.001. *P < 0.050; **P < 0.010; ***P < 0.001.
Fig. 3 Longitudinal CSF biomarkers change by baseline amyloid and tau status. Rates of change in CSF biomarkers per baseline amyloid (A) and tau (T) status are depicted (pT231/T231: n = 218, rest: n = 220). Individual rates of change are represented by dots. Trajectories for each group are displayed as boxplots, which were generated using linear mixed models (the central band represents the median, the lower and upper hinges correspond to the first and third quartiles and the whiskers depict the maximum/minimum value or 1.5 × interquartile range from the hinge, whichever is lower). Differences among all groups were assessed using Kruskal–Wallis tests and pairwise Wilcoxon tests were employed for post hoc comparisons. Asterisks indicate the P values from two-sided tests without correction for multiple comparisons. Longitudinal CSF data was available only in BioFINDER-2. Amyloid-positive participants were identified using a previously validated cutoff for CSF Aβ42/40 (CSF Aβ42/40 < 0.08). Tau positivity was determined based on tau-PET SUVR in the meta-ROI (Braak I-IV, SUVR > 1.32). ROI, region of interest. The actual P values for A−T− versus A+T− were P = 0.011 (pT205/T205); for A−T− versus A+T+ were P = 0.011 (pT181/T181), P = 0.014 (pT205/T205), P = 0.617 (pT217/T217) and P = 0.980 (pT231/T231); and for A+T− versus A+T+ were P = 0.788 (pT205/T205), P = 0.007 (pT231/T231). All other comparisons yielded P < 0.001. *P < 0.050; **P < 0.010; ***P < 0.001.CC BY · PubMed Central
Fig. 4 Associations between CSF biomarkers and MMSE. a,b, Associations between CSF biomarkers and MMSE are depicted for BioFINDER-2 (a, n = 342) and Knight ADRC (b, pT231/T231: n = 184, rest: n = 219) participants. The first two columns display scatter-plots of MTBR-tau243 (first column) and pT217/T217 (second column) against MMSE, color-coded by diagnosis and amyloid status. In the BioFINDER-2 cohort, orange dots represent MCI+ participants, while in the Knight ADRC cohort, they represent individuals with very mild AD. Linear regression models, adjusted for age, sex and years of education were utilized to obtain β coefficients, P values (asterisks) and R2 values shown in the plots. Scatter-plots for all biomarkers in both cohorts can be found in Extended Data Fig. 4. The third column shows the standardized β coefficients for all biomarkers, along with the associations of amyloid-PET and CSF Aβ42/40 (reversed) and tau-PET for comparison. Solid and dashed lines represent the standardized β coefficients (central dot) and 95% CI when including all participants or only amyloid-positive participants (BioFINDER-2, n = 261; Knight ADRC, n = 136, except for pT231/T231, where n = 117), respectively. Asterisks (crosses) indicate the highest or not significantly different standardized β coefficients in all (amyloid-positive only) participants within each cohort and outcome, based on bootstrapping. Non-AD participants from BioFINDER-2 were excluded from these analyses. Amyloid-positive participants were selected using previously validated cutoffs for CSF Aβ42/40 (CSF Aβ42/40 < 0.08 in BioFINDER-2 and CSF Aβ42/40 < 0.0673 in Knight ADRC). Association P values were derived from two-sided tests and bootstrapping p values were obtained from one-sided tests, all without adjustment for multiple comparisons. All p values for associations between CSF biomarkers and MMSE were <0.001.
Fig. 4 Associations between CSF biomarkers and MMSE. a,b, Associations between CSF biomarkers and MMSE are depicted for BioFINDER-2 (a, n = 342) and Knight ADRC (b, pT231/T231: n = 184, rest: n = 219) participants. The first two columns display scatter-plots of MTBR-tau243 (first column) and pT217/T217 (second column) against MMSE, color-coded by diagnosis and amyloid status. In the BioFINDER-2 cohort, orange dots represent MCI+ participants, while in the Knight ADRC cohort, they represent individuals with very mild AD. Linear regression models, adjusted for age, sex and years of education were utilized to obtain β coefficients, P values (asterisks) and R2 values shown in the plots. Scatter-plots for all biomarkers in both cohorts can be found in Extended Data Fig. 4. The third column shows the standardized β coefficients for all biomarkers, along with the associations of amyloid-PET and CSF Aβ42/40 (reversed) and tau-PET for comparison. Solid and dashed lines represent the standardized β coefficients (central dot) and 95% CI when including all participants or only amyloid-positive participants (BioFINDER-2, n = 261; Knight ADRC, n = 136, except for pT231/T231, where n = 117), respectively. Asterisks (crosses) indicate the highest or not significantly different standardized β coefficients in all (amyloid-positive only) participants within each cohort and outcome, based on bootstrapping. Non-AD participants from BioFINDER-2 were excluded from these analyses. Amyloid-positive participants were selected using previously validated cutoffs for CSF Aβ42/40 (CSF Aβ42/40 < 0.08 in BioFINDER-2 and CSF Aβ42/40 < 0.0673 in Knight ADRC). Association P values were derived from two-sided tests and bootstrapping p values were obtained from one-sided tests, all without adjustment for multiple comparisons. All p values for associations between CSF biomarkers and MMSE were <0.001.CC BY · PubMed Central
Fig. 5 Predicting quantitative amyloid-PET, tau-PET and MMSE continuous measures with CSF biomarkers. a,b, Linear regression models were employed to predict amyloid-PET (first column, BioFINDER-2, n = 256), tau-PET (second column, BioFINDER-2, n = 422) and cognition (MMSE, third column, BioFINDER-2, n = 342) in BioFINDER-2 (a) and Knight ADRC (b, n = 184). The base model included age and sex (and years of education for MMSE) as predictors. The parsimonious model was derived by using LASSO regression to identify the optimal combination of CSF biomarkers and demographic factors (age, sex and/or years of education). Biomarkers included in the parsimonious models are indicated by a black border and their names are shown in bold. The other models solely employed individual CSF biomarkers as predictors. For comparison, CSF Aβ42/40 and tau-PET were used as predictors in independent models for predicting all outcomes and cognition only, respectively. Model comparisons were conducted using an F-test for nested models or Vuong’s test for non-nested models. Non-AD cases were excluded from the BioFINDER-2 cohort for the cognition analyses.
Fig. 5 Predicting quantitative amyloid-PET, tau-PET and MMSE continuous measures with CSF biomarkers. a,b, Linear regression models were employed to predict amyloid-PET (first column, BioFINDER-2, n = 256), tau-PET (second column, BioFINDER-2, n = 422) and cognition (MMSE, third column, BioFINDER-2, n = 342) in BioFINDER-2 (a) and Knight ADRC (b, n = 184). The base model included age and sex (and years of education for MMSE) as predictors. The parsimonious model was derived by using LASSO regression to identify the optimal combination of CSF biomarkers and demographic factors (age, sex and/or years of education). Biomarkers included in the parsimonious models are indicated by a black border and their names are shown in bold. The other models solely employed individual CSF biomarkers as predictors. For comparison, CSF Aβ42/40 and tau-PET were used as predictors in independent models for predicting all outcomes and cognition only, respectively. Model comparisons were conducted using an F-test for nested models or Vuong’s test for non-nested models. Non-AD cases were excluded from the BioFINDER-2 cohort for the cognition analyses.CC BY · PubMed Central
Extended Data Fig. 1 CSF biomarkers by diagnosis. Levels of each CSF biomarkers by clinical diagnosis and amyloid status in the BioFINDER-2 cohort (n = 448). Amyloid-positive participants were selected based on CSF Aβ42/40 (CSF Aβ42/40 < 0.08). Larger pink dots represent two MAPT R406W mutation carriers (one CU- and the other in FTD groups), both amyloid-negative but with substantial tau-PET binding. In boxplots, central band represents the median of the group, the lower and upper hinges correspond to the first and third quartiles, and the whiskers represent the maximum/minimum value or the 1.5 IQR from the hinge, whatever is lower). Differences in CSF biomarker levels by diagnostic groups were tested using ANCOVA adjusted for age and sex. Post hoc analyses were performed two-sided using the Tuckey test. Actual p values are reported in Supplementary Table 1 for space reasons. p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: AD + , Alzheimer’s disease dementia amyloid positive; CBS, corticobasal syndrome; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; FTD, frontotemporal dementia; MCI + , mild cognitive impairment amyloid positive; MTBR, microtubule-binding region; PD, Parkinson’s disease; PDD, Parkinson’s disease dementia; PPA, primary progressive aphasia; PSP, progressive supranuclear palsy.
Extended Data Fig. 1 CSF biomarkers by diagnosis. Levels of each CSF biomarkers by clinical diagnosis and amyloid status in the BioFINDER-2 cohort (n = 448). Amyloid-positive participants were selected based on CSF Aβ42/40 (CSF Aβ42/40 < 0.08). Larger pink dots represent two MAPT R406W mutation carriers (one CU- and the other in FTD groups), both amyloid-negative but with substantial tau-PET binding. In boxplots, central band represents the median of the group, the lower and upper hinges correspond to the first and third quartiles, and the whiskers represent the maximum/minimum value or the 1.5 IQR from the hinge, whatever is lower). Differences in CSF biomarker levels by diagnostic groups were tested using ANCOVA adjusted for age and sex. Post hoc analyses were performed two-sided using the Tuckey test. Actual p values are reported in Supplementary Table 1 for space reasons. p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: AD + , Alzheimer’s disease dementia amyloid positive; CBS, corticobasal syndrome; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; FTD, frontotemporal dementia; MCI + , mild cognitive impairment amyloid positive; MTBR, microtubule-binding region; PD, Parkinson’s disease; PDD, Parkinson’s disease dementia; PPA, primary progressive aphasia; PSP, progressive supranuclear palsy.CC BY · PubMed Central
Extended Data Fig. 2 Associations between all CSF biomarkers and Aβ-PET. Associations between CSF biomarkers and amyloid-PET (Centiloid) in BioFINDER-2 (A) and Knight ADRC (B) participants. Linear regression models, adjusting for age and sex, were used to obtain standardized β and p values shown in the plots. In the BioFINDER-2 cohort, orange dots represent MCI+ participants whereas in the Kinght-ADRC cohort, represent very mild AD. *, p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: AD + , Alzheimer’s disease dementia amyloid positive; CL, Centiloids, CSF, cerebrospinal fluid; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; MCI + , mild cognitive impairment amyloid positive; MTBR, microtubule binding region; non-AD, non-Alzheimer’s disease dementia; PET, positron emission tomography.
Extended Data Fig. 2 Associations between all CSF biomarkers and Aβ-PET. Associations between CSF biomarkers and amyloid-PET (Centiloid) in BioFINDER-2 (A) and Knight ADRC (B) participants. Linear regression models, adjusting for age and sex, were used to obtain standardized β and p values shown in the plots. In the BioFINDER-2 cohort, orange dots represent MCI+ participants whereas in the Kinght-ADRC cohort, represent very mild AD. *, p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: AD + , Alzheimer’s disease dementia amyloid positive; CL, Centiloids, CSF, cerebrospinal fluid; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; MCI + , mild cognitive impairment amyloid positive; MTBR, microtubule binding region; non-AD, non-Alzheimer’s disease dementia; PET, positron emission tomography.CC BY · PubMed Central
Extended Data Fig. 3 Associations between all CSF biomarkers and tau-PET in the Braak I-IV ROI. Associations between CSF biomarkers and tau-PET in the Braak I-IV ROI (SUVR) in BioFINDER-2 (A) and Knight ADRC (B) participants. Linear regression models, adjusting for age and sex, were used to obtain standardized β and p-values shown in the plots. In the BioFINDER-2 cohort, orange dots represent MCI+ participants whereas in the Kinght-ADRC cohort, represent very mild AD. *, p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: AD + , Alzheimer’s disease dementia amyloid positive; CSF, cerebrospinal fluid; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; MCI + , mild cognitive impairment amyloid positive; MTBR, microtubule binding region; non-AD, non-Alzheimer’s disease dementia; PET, positron emission tomography, SUVR, standardized uptake value ratio.
Extended Data Fig. 3 Associations between all CSF biomarkers and tau-PET in the Braak I-IV ROI. Associations between CSF biomarkers and tau-PET in the Braak I-IV ROI (SUVR) in BioFINDER-2 (A) and Knight ADRC (B) participants. Linear regression models, adjusting for age and sex, were used to obtain standardized β and p-values shown in the plots. In the BioFINDER-2 cohort, orange dots represent MCI+ participants whereas in the Kinght-ADRC cohort, represent very mild AD. *, p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: AD + , Alzheimer’s disease dementia amyloid positive; CSF, cerebrospinal fluid; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; MCI + , mild cognitive impairment amyloid positive; MTBR, microtubule binding region; non-AD, non-Alzheimer’s disease dementia; PET, positron emission tomography, SUVR, standardized uptake value ratio.CC BY · PubMed Central
Extended Data Fig. 4 Associations between CSF biomarkers and tau-PET in different Braak regions. Associations between CSF biomarkers and tau-PET in Braak I (A), Braak III–IV (B) and Braak V–VI (C) regions. First two columns show scatter-plots of MTBR-tau243 (first column) and pT217/T217 (second column) and tau-PET in BioFINDER-2 participants (n = 443), colored by diagnosis and amyloid status. Linear regression models, adjusting for age and sex, were used to obtain standardized β, p-values (asterisks) and R2 shown in the plots. Third and fourth columns show standardized β of the association between each CSF biomarker and tau-PET in BioFINDER-2 and Knight ADRC participants (n = 219; except for pT231/T231 in which n = 184), respectively. Solid and dashed lines show standardized β (central dot) and 95%CI when all participants or only amyloid positive participants (BioFINDER-2: n = 287; Knight ADRC, n = 136) were included, respectively. Asterisks (crosses) show the highest or not significantly different standardized β in all (amyloid positive only) participants, in each cohort and outcome. Amyloid-positive participants were selected based on CSF Aβ42/40 previously validated cutoffs (CSF Aβ42/40 < 0.08 in BioFINDER-2 and CSF Aβ42/40 < 0.0673 in Knight ADRC). Association p-values were based on two-sided tests and bootstrapping p-values from one-sided tests, all unadjusted for multiple comparisons. All p-values from associations between CSF biomarkers and tau-PET shown in the scatter-plots were <0.001. *, p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: Aβ + , amyloid positive; AD + , Alzheimer’s disease dementia amyloid positive; CSF, cerebrospinal fluid; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; MCI + , mild cognitive impairment amyloid positive; MTBR, microtubule binding region; non-AD, non-Alzheimer’s disease dementia; PET, positron emission tomography; SUVR, standardized uptake value ratio.
Extended Data Fig. 4 Associations between CSF biomarkers and tau-PET in different Braak regions. Associations between CSF biomarkers and tau-PET in Braak I (A), Braak III–IV (B) and Braak V–VI (C) regions. First two columns show scatter-plots of MTBR-tau243 (first column) and pT217/T217 (second column) and tau-PET in BioFINDER-2 participants (n = 443), colored by diagnosis and amyloid status. Linear regression models, adjusting for age and sex, were used to obtain standardized β, p-values (asterisks) and R2 shown in the plots. Third and fourth columns show standardized β of the association between each CSF biomarker and tau-PET in BioFINDER-2 and Knight ADRC participants (n = 219; except for pT231/T231 in which n = 184), respectively. Solid and dashed lines show standardized β (central dot) and 95%CI when all participants or only amyloid positive participants (BioFINDER-2: n = 287; Knight ADRC, n = 136) were included, respectively. Asterisks (crosses) show the highest or not significantly different standardized β in all (amyloid positive only) participants, in each cohort and outcome. Amyloid-positive participants were selected based on CSF Aβ42/40 previously validated cutoffs (CSF Aβ42/40 < 0.08 in BioFINDER-2 and CSF Aβ42/40 < 0.0673 in Knight ADRC). Association p-values were based on two-sided tests and bootstrapping p-values from one-sided tests, all unadjusted for multiple comparisons. All p-values from associations between CSF biomarkers and tau-PET shown in the scatter-plots were <0.001. *, p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: Aβ + , amyloid positive; AD + , Alzheimer’s disease dementia amyloid positive; CSF, cerebrospinal fluid; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; MCI + , mild cognitive impairment amyloid positive; MTBR, microtubule binding region; non-AD, non-Alzheimer’s disease dementia; PET, positron emission tomography; SUVR, standardized uptake value ratio.CC BY · PubMed Central
Extended Data Fig. 5 Longitudinal CSF biomarkers trajectories by baseline “A” and “T” status. Individual (shaded lines) and group (bold lines) CSF biomarker levels trajectories over time based on their A/T baseline status. Statistical differences to the reference group (A-T-) are shown with asterisks with the appropriate color. Longitudinal CSF data was only available in BioFINDER-2. Amyloid-positive participants were selected based on a CSF Aβ42/40 previously validated cutoff (CSF Aβ42/40 < 0.08). Tau positivity was assessed based on tau-PET SUVR in the meta-ROI (Braak I-IV SUVR > 1.32). *, p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: A-T-, amyloid and tau negative; A + T-, amyloid positive and tau negative; A + T + , amyloid positive, tau positive; CSF, cerebrospinal fluid; MTBR, microtubule binding region; PET, positron emission tomography.
Extended Data Fig. 5 Longitudinal CSF biomarkers trajectories by baseline “A” and “T” status. Individual (shaded lines) and group (bold lines) CSF biomarker levels trajectories over time based on their A/T baseline status. Statistical differences to the reference group (A-T-) are shown with asterisks with the appropriate color. Longitudinal CSF data was only available in BioFINDER-2. Amyloid-positive participants were selected based on a CSF Aβ42/40 previously validated cutoff (CSF Aβ42/40 < 0.08). Tau positivity was assessed based on tau-PET SUVR in the meta-ROI (Braak I-IV SUVR > 1.32). *, p < 0.050; **, p < 0.010; ***, p < 0.001. Abbreviations: A-T-, amyloid and tau negative; A + T-, amyloid positive and tau negative; A + T + , amyloid positive, tau positive; CSF, cerebrospinal fluid; MTBR, microtubule binding region; PET, positron emission tomography.CC BY · PubMed Central
Extended Data Fig. 6 Associations between all CSF biomarkers and MMSE. In BioFINDER-2 cohort (A), orange dots represent MCI+ participants whereas in the Kinght-ADRC cohort (B), represent very mild AD. Linear regression models, adjusting for age, sex and years of education were used to obtain standardized β and p-values shown in the plots. *, p < 0.50; **, p < 0.010; ***, p <0.001. Abbreviations: AD + , Alzheimer’s disease dementia amyloid positive; CSF, cerebrospinal fluid; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; MCI + , mild cognitive impairment amyloid positive; MMSE, Mini Mental State Examination; MTBR, microtubule binding region; PET, positron emission tomography, SD, standard deviation; SUVR, standardized uptake value ratio.
Extended Data Fig. 6 Associations between all CSF biomarkers and MMSE. In BioFINDER-2 cohort (A), orange dots represent MCI+ participants whereas in the Kinght-ADRC cohort (B), represent very mild AD. Linear regression models, adjusting for age, sex and years of education were used to obtain standardized β and p-values shown in the plots. *, p < 0.50; **, p < 0.010; ***, p <0.001. Abbreviations: AD + , Alzheimer’s disease dementia amyloid positive; CSF, cerebrospinal fluid; CU-, cognitively unimpaired amyloid negative; CU + , cognitively unimpaired amyloid positive; MCI + , mild cognitive impairment amyloid positive; MMSE, Mini Mental State Examination; MTBR, microtubule binding region; PET, positron emission tomography, SD, standard deviation; SUVR, standardized uptake value ratio.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 2

  1. Ashton, N. J. et al. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nat. Med. 28, 2555–2562 (2022). · DOI · Paper page
  2. Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 80, 188–199 (2023). · DOI · Paper page

Cited by

See all 282

Metadata

Authors
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., Pichet Binette, A., Palmqvist, S., Sato, C., Sachdev, P., Koyama, A., Gordon, B. A., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., Mattsson-Carlgren, N., Stomrud, E., Ossenkoppele, R., Schindler, S. E., Hansson, O., & Bateman, R. J.
Affiliations
  • Washington University in St. Louis (US)
  • Lund University (SE)
  • Eisai (United States) (US)
Corresponding author
  • Hansson, Oskar
  • Bateman, Randall J.
Venue
Nature Medicine
Published
2023-07-13
Volume
29
Issue
8
Pages
1954-1963
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4384206832
Cited by
249
References
68
Citations by year
2026: 53 · 2025: 99 · 2024: 80 · 2023: 17
FWCI
44.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • Foundation for Barnes-Jewish Hospital (P30 AG066444)
  • Cure Alzheimer's Fund
  • Hope Center for Neurological Disorders
  • Australian Government
  • GHR Foundation
  • European Commission (HORIZON2020)
  • Lunds Universitet
  • Eisai
  • Knut och Alice Wallenbergs Stiftelse (2017‐0383)
  • Vetenskapsrådet (2016-00906, FO2021-0293, 2018-, 2017-00383)
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028, 2020-0314)
  • Skånes universitetssjukhus (2020-O000028)
  • Marcus och Amalia Wallenbergs minnesfond (2015.0125)
  • Parkinsonfonden (1280/20)
  • Avid Radiopharmaceuticals
  • Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis (P30 AG066444)
  • National Institute on Aging (P01AG003991, P30AG066444, R01AG070941, P01AG026276)
  • National Institute of Neurological Disorders and Stroke (P30NS048056)
  • HORIZON EUROPE Marie Sklodowska-Curie Actions (101061836)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
tau aggregates, tau tangles, Alzheimer's disease, cerebrospinal fluid biomarkers, phosphorylated tau, tau PET, amyloid PET, cognitive impairment
MeSH terms
Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41591-023-02443-z
The paper
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., Pichet Binette, A., Palmqvist, S., Sato, C., Sachdev, P., Koyama, A., Gordon, B. A., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., . . . Bateman, R. J. (2023). CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nature Medicine. https://doi.org/10.1038/s41591-023-02443-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.